Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Naoki Fujita is a leading urologic oncologist whose research centers on the intersection of frailty, geriatric assessment, and surgical outcomes in prostate and bladder cancer. His most impactful work has established the Geriatric 8 (G8) screening tool as a critical instrument for evaluating frailty in prostate cancer patients, demonstrating its association with treatment decisions, postoperative pain, and quality of life. In a landmark 2020 study with 40 citations, Dr. Fujita prospectively evaluated G8 in 540 patients, revealing how frailty scores correlate with disease stage management. His FRAP study (17 citations) further showed that frailty independently predicts moderate-to-severe pain after robot-assisted laparoscopic prostatectomy, while the FRARP-QL study (12 citations) demonstrated its longitudinal effects on quality of life and urinary symptoms. Dr. Fujita has also advanced surgical oncology by comparing robot-assisted versus open radical cystectomy for muscle-invasive bladder cancer, examining peritoneal carcinomatosis risk and oncologic outcomes. His work on neoadjuvant chemohormonal therapy for high-risk prostate cancer and outcomes in men aged 75+ has helped refine treatment paradigms for older, frailer patients, making him a pivotal figure in geriatric urologic oncology.